

**FIFTH BRISTOL OPIOID CONFERENCE**  
In association with the EAPC and the EPCRC

“Revising the EAPC recommendations on  
opioids in cancer pain”

**Monday 8 & Tuesday 9 February 2010**

**Venue: The Bristol Hotel, Prince Street, Bristol, BS1 4QF**



CPD accreditation applied for

## Monday 8 February

09.00-9.30	<b>Registration/ Welcome – Chair: Karen Forbes</b>	
09.30-10.00	Evidence based medicine: what is the evidence that it has made a difference?	Henry McQuay
10.00-10.15	Cancer pain relief: what are the issues in 2009?	Geoffrey Hanks
10.15-10.30	Opioid availability in Europe: the ESMO/EAPC study	Franco de Conno
10.30-10.50	Assessment and classification of cancer pain: are international recommendations emerging?	Stein Kaasa
10.50-11.20	<b>Coffee</b>	
11.20-11.35	The EPCRC Opioid Guidelines Project	Augusto Caraceni
<u>Step III opioid of first choice and initiating therapy</u>		
11.35-11.50	Step III opioid of first choice	Augusto Caraceni
11.50-12.05	Dose titration	Pål Klepstad
12.05-12.15	<b>Discussion</b>	Jim Cleary
<u>Alternative step III opioids and indications</u>		
12.15-12.30	Oxycodone	Colette Reid
12.30-12.45	Methadone	Nathan Cherny
12.45-13.45	<b>Lunch</b>	
13.45-14.00	Hydromorphone	Augusto Caraceni
14.00-14.15	Transdermal fentanyl/transdermal buprenorphine	Marco Maltoni/David Tassinari
14.15-14.45	<b>Discussion</b>	Eduardo Bruera
14.45-15.15	<b>Tea</b>	
<u>Patients with renal and hepatic impairment</u>		
15.15-15.30	Patients with liver impairment	Magdi Hanna
15.30-15.45	Patients with renal impairment	Karen Forbes & Sam King
15.45-16.15	<b>Discussion/Review of the day</b>	David Currow
16.15	<b>Close</b>	

## Tuesday 9 February

09.00-9.30 **Coffee**

09.30-10.00 How well do we treat cancer pain?

Kathy Foley

### Patients with difficult pain

10.00-10.15 Breakthrough pain

John Zeppetella

10.15-10.30 Opioid rotation

Stein Kaasa/Ola Dale

10.30-10.45 Equianalgesic dose ratios

Sebastiano Mercadante

10.45-11.15 **Discussion**

David Currow

11.15-11.45 **Coffee**

11.45-12.00 Spinal opioids

Per Sjøgren

12.00-12.15 Other routes of administration

Lukas Radbruch

12.15-12.30 Opioid combinations

Marie Fallon

12.30-13.00 **Discussion**

Jim Cleary

13.00-14.00 **Lunch**

### NSAIDs and Adjuvants

14.00-14.15 NSAIDs

Maria Nabal

14.15-14.30 Antidepressants, anticonvulsants

Mike Bennett

14.30-14.45 Ketamine

Eija Kalso

14.45-15.00 **Discussion**

Eduardo Bruera

15.00-15.30 **Tea**

### Opioid side-effects

15.30-15.45 Gastrointestinal side effects of opioids

Gitte Juhl

15.45-16.00 Central side effects of opioids

Paddy Stone

16.00-16.30 **Discussion and Close**

Augusto Caraceni

## Faculty

*The EAPC guidelines on opioids for cancer pain relief have been widely influential (BMJ 1996;312:823-6 and Br J Cancer 2001;84:587-93). The guidelines are being updated as part of the European Palliative Care Research Collaboration (EPCRC), funded by the 6<sup>th</sup> Framework Programme of the EU. 17 research groups are involved in the revision of the guidelines and they provide the faculty for this conference. Each group has formulated a clinical recommendation on the basis of a systematic review of evidence for each topic to be included in the guidelines. Eminent authorities from outside Europe will act as discussants.*

- Prof Mike Bennett, International Observatory on End of Life Care, Lancaster University, UK
- Prof Eduardo Bruera, MD Anderson Hospital, Houston, Texas, USA
- Dr Augusto Caraceni, National Cancer Institute, Milan, Italy
- Dr Nathan Cherny, Shaare Zedek Medical Centre, Jerusalem, Israel
- Dr Jim Cleary, University of Wisconsin, Madison, USA
- Prof Ola Dale, Norwegian University of Science and Technology, Trondheim, Norway
- Dr Franco de Conno, National Cancer Institute, Milan, Italy
- Prof Marie Fallon, University of Edinburgh, UK
- Dr Kathy Foley, Memorial Sloan Kettering Cancer Center, New York, USA
- Prof Karen Forbes, University of Bristol, UK
- Prof Geoffrey Hanks, University of Bristol, UK
- Dr Magdi Hanna, King's College London, UK
- Dr Gitte Juhl, Herlev University Hospital, Herlev, Denmark
- Prof Stein Kaasa, University of Trondheim, Norway
- Dr Eija Kalso, Helsinki Central Hospital, Finland
- Dr Samuel King, University of Bristol, UK
- Prof Pål Klepstad, Norwegian University of Science and Technology, Trondheim, Norway
- Dr Marco Maltoni, Valerio Grassi Hospice, Forlimpopoli, Italy
- Prof Henry McQuay, Nuffield Professor of Anaesthetics, University of Oxford, UK
- Dr Sebastiano Mercadante, La Maddalena Cancer Centre, Palermo, Italy
- Dr Maria Nabal, Hospital Universitario Arnau de Vilanova, Spain
- Prof Lukas Radbruch, University of Aachen, Germany
- Dr Colette Reid, University of Bristol, UK
- Dr Per Sjogren, Rigshospitalet, Copenhagen, Denmark
- Dr Paddy Stone, St George's, University of London, UK
- Dr Davide Tassinari, City Hospital, Rimini, Italy
- Dr John Zeppetella, St Clare Hospice, Essex, UK

**Registration and fees**

Doctors £295

Clinical Nurse Specialists £175

Title..... First Name.....Surname.....

Job title.....

Address.....

.....

Tel.....Fax.....

Email.....

Special dietary / other requirements.....

**Payment**

**By cheque** - cheque for £..... is enclosed (Make cheque payable to "University of Bristol")

**By credit card** - please debit my Visa/Mastercard/Switch

Name of card holder.....

Card number \_ \_ \_ \_ / \_ \_ \_ \_ / \_ \_ \_ \_ / \_ \_ \_ \_

Valid from.....Expires end ..... Security code \_ \_ \_ Issue No\_

Signature

**By invoice** – please send an invoice to:

Name.....

Organisation.....

Address.....

.....

Cancellations must be made in writing and are subject to a 10% administration fee. No refunds will be made for cancellations notified **within 2 weeks** of the event, but substitute delegates will be accepted.

Please return completed registration form to: Debbie Ashby, Department of Palliative Medicine, Bristol Haematology and Oncology Centre, Horfield Road, Bristol, BS2 8ED, UK

Tel: + 44 (0)117 342 3336 Fax: +44 (0)117 342 3865 [Debbie.Ashby@bristol.ac.uk](mailto:Debbie.Ashby@bristol.ac.uk)

*The University of Bristol maintains a policy in accordance with the Data Protection Act.*